Translational Regenerative Medicine Market Report 2024-2034
상품코드:1424907
리서치사:Visiongain
발행일:2024년 02월
페이지 정보:영문 270 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 중개 재생의료 시장 규모는 2034년까지 CAGR 24.3%로 성장할 것으로 예측되고 있습니다.
세계의 헬스케어 상황에서는 만성질환의 확대에 의해 패러다임 전환이 일어나고 있습니다. 심혈관질환, 당뇨병, 신경변성질환, 자가면역질환 등의 질환은 세계의 의료제도에 큰 부담을 초래하고 있습니다. 이러한 건강 위기의 증가에 의해 중개 재생의료(TRM)라는 분야가 만성질환의 근본 원인에 대처하는 혁신적인 솔루션을 제공하는 희망의 등불로 부상하고 있습니다.
줄기세포 치료, 조직공학, 기타 재생 어프로치는 단순히 증상을 관리하는 것이 아니라 근본적인 원인에 대처하는 것으로 만성질환의 치료 상황을 변화시킬 가능성을 내포하고 있습니다. 중개 재생의료는 개별 환자 요구에 맞춘 맞춤형 치료의 개발을 가능하게 합니다. 이 어프로치는 환자 반응의 불균일성이 일반적인 만성질환에서 특히 적합합니다. 유도만능줄기세포(iPSC) 및 성체 줄기세포의 사용을 포함한 줄기세포 연구의 진보도 다양한 재생의 가능성을 제공하고 있습니다. 줄기세포를 이용한 치료법은 손상된 췌장 세포를 대체하는 것으로 정상적인 인슐린 생산을 회복시킬 수 있는 당뇨병 등의 질환에 대해 유망시되고 있습니다.
세계의 중개 재생의료 시장을 조사했으며, 시장 개요, 시장 성장에 대한 영향요인 및 시장 기회의 분석, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 리포트 개요
제2장 주요 요약
제3장 시장 개요
주요 조사 결과
시장 역학
시장 촉진요인
시장 억제요인
시장 기회
COVID-19의 영향 분석
Porter's Five Forces 분석
PEST 분석
제4장 중개 재생의료 시장 분석 : 제품별
주요 조사 결과
시장 매력 지수
시장 규모의 추이·예측
줄기세포 요법
시장 규모의 추이·예측
시장 규모의 추이·예측 : 지역별
시장 점유율 : 지역별
자가 줄기세포 요법
동종이계 줄기세포 요법
인체조직 공학
시장 규모의 추이·예측
시장 규모의 추이·예측 : 지역별
시장 점유율 : 지역별
스캐폴드
하이드로겔
유전자 치료
기타
시장 규모의 추이·예측 : 지역별
시장 점유율 : 지역별
제5장 중개 재생의료 시장 분석 : 용도별
주요 조사 결과
시장 매력 지수
시장 규모의 추이·예측
종양
피부과
근골격계
신경 내과
심장혈관
창상 치유
안과
기타
시장 규모의 추이·예측 : 지역별
시장 점유율 : 지역별
제6장 지역별 중개 재생의료 시장 분석
주요 조사 결과
시장 규모의 추이·예측
제7장 북미의 중개 재생의료 시장 분석
제8장 유럽의 중개 재생의료 시장 분석
제9장 아시아태평양의 중개 재생의료 시장 분석
제10장 라틴아메리카의 중개 재생의료 시장 분석
제11장 중동 및 아프리카의 중개 재생의료 시장 분석
제12장 기업 개요
경쟁 구도
전략적 전망
Amgen Inc.
Anterogen Co., Ltd.
AVITA Medical, Inc.
Biosolutions Ltd.
bluebird bio, Inc.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
Integra LifeSciences
Mesoblast Ltd.
Novartis AG
Organogenesis Inc.
Sarepta Therapeutics, Inc.
Smith+Nephew
TERUMO BCT, INC.
제13장 결론·권장사항
Visiongain에 의한 결론
참여 기업에 대한 권장사항
KSA
영문 목차
영문목차
The global Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034
The Translational Regenerative Medicine Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Rising Chronic Diseases Driving Industry Growth
The global landscape of healthcare is witnessing a paradigm shift driven by the escalating prevalence of chronic diseases. Conditions such as cardiovascular diseases, diabetes, neurodegenerative disorders, and autoimmune diseases pose a significant burden on healthcare systems worldwide. In response to this growing health crisis, the field of Translational regenerative medicine (TRM) has emerged as a beacon of hope, offering innovative solutions to address the root causes of these chronic ailments. Translational regenerative medicine focuses on harnessing the body's innate regenerative capabilities to repair, replace, or regenerate damaged tissues and organs. Stem cell therapies, tissue engineering, and other regenerative approaches hold the potential to revolutionize the treatment landscape for chronic diseases by addressing the underlying causes rather than merely managing symptoms. Translational regenerative medicine allows for the development of personalized therapies tailored to individual patient needs. This approach is particularly relevant in the context of chronic diseases where heterogeneity in patient responses is common. Advances in stem cell research, including the use of induced pluripotent stem cells (iPSCs) and adult stem cells, offer a diverse range of regenerative possibilities. Stem cell-based therapies hold promise for conditions such as diabetes, where the replacement of damaged pancreatic cells could restore normal insulin production.
High Development Costs Associated with Translational Regenerative Medicine
The initial phases of developing translational regenerative medicine therapies involve extensive research to understand the underlying biology and mechanisms. This early-stage research requires funding for laboratory equipment, personnel, and consumables. Clinical trials represent a major portion of the development costs. These trials are essential for evaluating the safety and efficacy of regenerative therapies in human subjects. Costs include patient recruitment, monitoring, regulatory compliance, and data analysis, all of which demand substantial financial resources. Transitioning from laboratory-scale production to large-scale manufacturing presents unique challenges. Ensuring the reproducibility, quality, and safety of regenerative therapies on a larger scale requires investment in manufacturing infrastructure and process optimization. Successfully bringing a regenerative medicine product to market is just the beginning. Companies face additional costs related to market access, including marketing, distribution, and post-marketing surveillance. These activities are crucial for ensuring widespread adoption and continued success.
What Questions Should You Ask before Buying a Market Research Report?
How is the Translational Regenerative Medicine Market evolving?
What is driving and restraining the Translational Regenerative Medicine Market?
How will each Translational Regenerative Medicine submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each Translational Regenerative Medicine submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading Translational Regenerative Medicine Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
What are the Translational Regenerative Medicine projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of Translational
Regenerative Medicine projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the Translational Regenerative Medicine Market?
Where is the Translational Regenerative Medicine Market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Translational Regenerative Medicine Market today, and over the next 10 years:
Our 270-page report provides 104 tables and 144 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Translational Regenerative Medicine Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report
By Product
Stem Cell Therapy: Autologous, Allogenic
Tissue Engineering: Scaffold, Hydrogels
Gene Therapy
Others
By Application
Oncology
Dermatology
Musculoskeletal
Neurology
Cardiovascular
Wound Healing
Ophthalmology
Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 17 leading national markets:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
MEA
GCC
South Africa
Rest of MEA
The report also includes profiles and for some of the leading companies in the Translational Regenerative Medicine Market 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies profiled in the report
Amgen Inc.
Anterogen Co., Ltd.
AVITA Medical, Inc.
Biosolutions Ltd.
bluebird bio, Inc.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
Integra LifeSciences
Mesoblast Ltd.
Novartis AG
Organogenesis Inc.
Sarepta Therapeutics, Inc.
Smith+Nephew
TERUMO BCT, INC.
Overall world revenue for Translational Regenerative Medicine Market, 2024 to 2034 in terms of value the market will surpass US$77.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Translational Regenerative Medicine Market 2024 to 2034 report help you?
In summary, our 270-page report provides you with the following knowledge:
Revenue forecasts to 2034 for Translational Regenerative Medicine Market 2024 to 2034, with forecasts for product and application each forecasted at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Translational Regenerative Medicine Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Translational Regenerative Medicine Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Translational Regenerative Medicine Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Translational Regenerative Medicine Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Strategic Activities and Collaborations
3.2.1.2 Rise in Research and Development Projects
3.2.1.3 Surging Government Support
3.2.1.4 Growing Focus on Personalized Medicine
3.2.1.5 Emerging Applications in New Therapeutic Areas
3.2.1.6 Increasing Collaborations and Partnerships by Major Market Players
3.2.1.7 Increasing Regulatory Approvals in Regenerative Medicine
3.2.2 Market Restraining Factors
3.2.2.1 Substantial Number of Product Recalls
3.2.2.2 Unapproved Products in the Market
3.2.2.3 Reimbursement Policies
3.2.2.4 High Cost of Treatments
3.2.3 Market Opportunities
3.2.3.1 Growing Research Partnership in Developed and Developing Countries Across the Globe
3.2.3.2 Growing Awareness About the Advances in Medical Research
3.2.3.3 Growing Investment and Funding
3.2.3.4 Harnessing the Potential of 3D Printing
3.2.3.5 Integration with Artificial Intelligence and Big Data
3.2.3.6 Growing Number of Organ Transplants
3.3 COVID-19 Impact Analysis
3.4 Porter's Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Translational Regenerative Medicine Market Analysis by Product
4.1 Key Findings
4.2 Application Segment: Market Attractiveness Index
4.3 Translational Regenerative Medicine Market Size Estimation and Forecast by Product
4.4 Stem Cell Therapy
4.4.1 Translational Regenerative Medicine Market Size Estimation and Forecast by Stem Cell Therapy
4.4.2 Market Size by Region, 2024-2034 (US$ Billion)
4.4.3 Market Share by Region, 2024 & 2034 (%)
4.4.4 Autologous Stem Cell Therapy
4.4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.4.2 Market Share by Region, 2024 & 2034 (%)
4.4.5 Allogenic
4.4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.5.2 Market Share by Region, 2024 & 2034 (%)
4.5 Tissue Engineering
4.5.1 Translational Regenerative Medicine Market Size Estimation and Forecast by Tissue Engineering
4.5.2 Market Size by Region, 2024-2034 (US$ Billion)
4.5.3 Market Share by Region, 2024 & 2034 (%)
4.5.4 Scaffold
4.5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.4.2 Market Share by Region, 2024 & 2034 (%)
4.5.5 Hydrogels
4.5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Gene Therapy
4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.6.2 Market Share by Region, 2024 & 2034 (%)
4.7 Others
4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
4.7.2 Market Share by Region, 2024 & 2034 (%)
5 Translational Regenerative Medicine Market Analysis by Application
5.1 Key Findings
5.2 Application Segment: Market Attractiveness Index
5.3 Translational Regenerative Medicine Market Size Estimation and Forecast by Application
5.4 Oncology
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Dermatology
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Musculoskeletal
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Neurology
5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Cardiovascular
5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
5.8.2 Market Share by Region, 2024 & 2034 (%)
5.9 Wound Healing
5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
5.9.2 Market Share by Region, 2024 & 2034 (%)
5.10 Ophthalmology
5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
5.10.2 Market Share by Region, 2024 & 2034 (%)
5.11 Others
5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
5.11.2 Market Share by Region, 2024 & 2034 (%)
6 Translational Regenerative Medicine Market Analysis by Region
6.1 Key Findings
6.2 Regional Market Size Estimation and Forecast
7 North America Translational Regenerative Medicine Market Analysis
7.1 Key Findings
7.2 North America Translational Regenerative Medicine Market Attractiveness Index
7.3 North America Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
7.4 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Country
7.5 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Product
7.6 North America Translational Regenerative Medicine Market Size Estimation and Forecast by Application
7.7 U.S. Translational Regenerative Medicine Market Analysis
7.8 Canada Translational Regenerative Medicine Market Analysis
8 Europe Translational Regenerative Medicine Market Analysis
8.1 Key Findings
8.2 Europe Translational Regenerative Medicine Market Attractiveness Index
8.3 Europe Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
8.4 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Country
8.5 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Product
8.6 Europe Translational Regenerative Medicine Market Size Estimation and Forecast by Application
8.7 Germany Translational Regenerative Medicine Market Analysis
8.8 France Translational Regenerative Medicine Market Analysis
8.9 UK Translational Regenerative Medicine Market Analysis
8.10 Italy Translational Regenerative Medicine Market Analysis
8.11 Spain Translational Regenerative Medicine Market Analysis
8.12 Russia Translational Regenerative Medicine Market Analysis
8.13 Rest of Europe Translational Regenerative Medicine Market Analysis
9 Asia Pacific Translational Regenerative Medicine Market Analysis
9.1 Key Findings
9.2 Asia Pacific Translational Regenerative Medicine Market Attractiveness Index
9.3 Asia Pacific Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
9.4 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Country
9.5 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Product
9.6 Asia Pacific Translational Regenerative Medicine Market Size Estimation and Forecast by Application
9.7 Japan Translational Regenerative Medicine Market Analysis
9.8 China Translational Regenerative Medicine Market Analysis
9.9 India Translational Regenerative Medicine Market Analysis
9.10 Australia Translational Regenerative Medicine Market Analysis
9.11 South Korea Translational Regenerative Medicine Market Analysis
9.12 Rest of Asia Pacific Translational Regenerative Medicine Market Analysis
10 Latin America Translational Regenerative Medicine Market Analysis
10.1 Key Findings
10.2 Latin America Translational Regenerative Medicine Market Attractiveness Index
10.3 Latin America Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
10.4 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Country
10.5 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Product
10.6 Latin America Translational Regenerative Medicine Market Size Estimation and Forecast by Application
10.7 Brazil Translational Regenerative Medicine Market Analysis
10.8 Mexico Translational Regenerative Medicine Market Analysis
10.9 Rest of Latin America Translational Regenerative Medicine Market Analysis
11 MEA Translational Regenerative Medicine Market Analysis
11.1 Key Findings
11.2 MEA Translational Regenerative Medicine Market Attractiveness Index
11.3 MEA Translational Regenerative Medicine Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Country
11.5 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Product
11.6 MEA Translational Regenerative Medicine Market Size Estimation and Forecast by Application
11.7 GCC Translational Regenerative Medicine Market Analysis
11.8 South Africa Translational Regenerative Medicine Market Analysis
11.9 Rest of MEA Translational Regenerative Medicine Market Analysis
